National Tourism Day, a mystery virus on a cruise ship, WHO launches a free clinical trials course, Congress wants to ban China data, and FDA is piloting AI-enabled early phase trials. Light vibes, heavy implications.

In this episode, Brad and Denali riff on how all of this actually hits sites, sponsors, and patients:

In this episode we cover: WHO's new free, self-paced clinical trials course

4.5 hours, 9 themes (ethics, GCP, community engagement, operational feasibility, etc.) Is this just another GCP box-check… or something more practical for real-world sites? Pandemic preparedness & the latest cruise ship outbreak

Person-to-person transmission, high fatality, and what this says about "the age of pandemics" How global standards and infrastructure (WHO, Warp Speed, etc.) either help… or fall apart House panel move to ban clinical data from China, Russia, Iran, North Korea

Concerns about IP theft, ethics, and data quality vs. the real motive: geopolitics and money What happens to diversity, inclusion, and global enrollment if we shut out huge populations? FDA's push to speed R&D & the AI-enabled early phase trials pilot

Mirroring Australia's clinical notification model Public comments on the AI pilot: signal vs. noise, and who's just selling their product Paradigm's role, direct-to-FDA data streaming, and whether oncology is the worst place to start Sites, CROs, and sponsors caught in the middle

Are we actually making trials faster and more efficient, or just reshuffling paperwork? Why free, credible training matters for developing countries and new site staff

If you care about site operations, GCP that actually means something, global data politics, AI in clinical trials, and how any of this reaches coordinators and patients, this one's for you.